NASDAQ:PDSB PDS Biotechnology Q3 2026 Earnings Results & Report $0.92 -0.06 (-6.12%) As of 12:42 PM Eastern This is a fair market value price provided by Massive. Learn more. PDS Biotechnology missed analyst earnings expectations in its Q3 2026 results, released November 13, 2026. The company reported EPS of -$0.11 versus the -$0.09 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 13, 2026TimeBefore Market OpensConference Call8:00 AM ET PDS Biotechnology EPS ResultsActual EPS-$0.11Consensus EPS -$0.09Beat/MissMissed by -$0.02One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersPDS Biotechnology Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) PDS Biotechnology Q3 2026 Earnings FAQ Did PDS Biotechnology beat earnings estimates for Q3 2026? PDS Biotechnology (NASDAQ:PDSB) reported earnings of -$0.11 per share for Q3 2026, missing the consensus estimate of -$0.09. The report was announced on Friday, November 13, 2026. PDS Biotechnology Earnings HeadlinesPDS Biotech Reports Third Quarter 2026 Financial Results4 hours ago | globenewswire.comPDS Biotech Announces Exercise of Warrants by NantWorks for Approximately $3.9 Million in Gross ProceedsNovember 10 at 12:22 PM | finance.yahoo.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.November 13 at 1:00 AM | Weiss Ratings (Ad)PDS Biotechnology (PDSB) Expected to Release Quarterly Earnings on ThursdayNovember 5, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB) and Lineage Therap (LCTX)October 30, 2026 | theglobeandmail.comPDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of DirectorsOctober 20, 2026 | globenewswire.comSee More PDS Biotechnology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like PDS Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PDS Biotechnology and other key companies, straight to your email. Email Address About PDS BiotechnologyPDS Biotechnology (NASDAQ:PDSB) (NASDAQ:PDSB) is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and infectious diseases. The company’s research is based primarily on its Versamune platform, a proprietary technology designed to stimulate targeted immune responses, including the activation of cancer-fighting T cells and natural killer cells. Its lead investigational product, PDS0101, is an immunotherapy candidate designed to target human papillomavirus type 16 (HPV16), a viral strain associated with several cancers. PDS0101 is being evaluated alone and in combination with other treatments, including immune checkpoint inhibitors, for HPV16-positive cancers. The company is also developing additional Versamune-based candidates for oncology and infectious-disease applications. These products remain investigational and are not approved for commercial use. Founded in 2005 and headquartered in Florham Park, New Jersey, PDS Biotechnology conducts its development activities through clinical research programs and collaborations with academic, government and industry partners. The company is led by President and Chief Executive Officer Frank Bedu-Addo. Its programs are directed toward patients in the United States and other international markets where relevant clinical trials are conducted.View PDS Biotechnology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid?3 Pharmaceutical Stocks That Offer Safety and GrowthFirefly Aerospace Lights Up a High-Risk Space Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
